Free Trial

What is William Blair's Estimate for DNTH FY2025 Earnings?

Dianthus Therapeutics logo with Medical background

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at William Blair issued their FY2025 EPS estimates for shares of Dianthus Therapeutics in a research note issued on Wednesday, July 2nd. William Blair analyst M. Minter anticipates that the company will earn ($3.26) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. William Blair also issued estimates for Dianthus Therapeutics' FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($2.99) EPS, FY2028 earnings at ($3.11) EPS and FY2029 earnings at ($3.81) EPS.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.81 million.

A number of other analysts have also recently weighed in on DNTH. Robert W. Baird decreased their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Guggenheim restated a "buy" rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of "Buy" and an average price target of $53.00.

Read Our Latest Stock Report on Dianthus Therapeutics

Dianthus Therapeutics Trading Down 3.2%

Shares of NASDAQ DNTH traded down $0.60 during mid-day trading on Friday, reaching $18.25. The company had a trading volume of 215,078 shares, compared to its average volume of 264,657. The firm has a 50 day simple moving average of $18.85 and a two-hundred day simple moving average of $20.42. The stock has a market cap of $586.92 million, a P/E ratio of -6.34 and a beta of 1.38. Dianthus Therapeutics has a 52-week low of $13.37 and a 52-week high of $32.27.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new position in Dianthus Therapeutics during the fourth quarter worth about $33,000. US Bancorp DE raised its position in shares of Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after purchasing an additional 1,510 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in Dianthus Therapeutics in the 4th quarter valued at approximately $59,000. GAMMA Investing LLC grew its holdings in Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after buying an additional 3,758 shares during the last quarter. Finally, AlphaQuest LLC grew its holdings in Dianthus Therapeutics by 273.1% during the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after buying an additional 3,072 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Recommended Stories

Earnings History and Estimates for Dianthus Therapeutics (NASDAQ:DNTH)

Should You Invest $1,000 in Dianthus Therapeutics Right Now?

Before you consider Dianthus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.

While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines